Financial Well-Being Series: Invest in Yourself – Video

January 29th, 2012 by FetDiuthscuch No comments »


25-01-2012 07:16 The Multiple Sclerosis Association of America in coordination with the National Disability Institute are pleased to present “Invest in Yourself” – the fourth in a series of four webinars designed to assist the MS community in learning about strategies to protect and improve their financial well-being. These programs offer hands-on guidance specifically tailored to the unique needs and interests of people living with MS. The Multiple Sclerosis Association of America (MSAA) is a national nonprofit organization dedicated to enriching the quality of life for everyone affected by multiple sclerosis (MS). MSAA provides ongoing support and direct services to individuals with MS and the people close to them. The National Disability Institute is a nonprofit organization based in Washington, DC dedicated to improving the financial stability and mobility of persons with disabilities and their families.

See the rest here:
Financial Well-Being Series: Invest in Yourself – Video

Regina woman a walking miracle

January 28th, 2012 by angerurry No comments »

REGINA — For more than two years, Dionne and Graham Warner
hoped for a miracle — and when it finally arrived Tuesday, they
were numb.

Then euphoric.

“The doctor walked in with no file in his hand,” Graham said.
“I thought, ‘That’s strange.’ But he didn’t need a file to tell
us.”

The doctor told Dionne, “You continue to be my walking
miracle.”

Her Regina oncologist told them a recent positron emission
tomography (PET) scan done in Winnipeg shows the 46-year-old
woman has no trace of cancer and is in remission.

Since 1995, Dionne has waged wars on breast cancer, brain
cancer and two bouts of liver cancer. The couple’s latest
battle with cancer began in December 2009 when Dionne was
diagnosed with Stage 4 cancer in her lungs, bones and liver.
Her oncologist told her she was a week to 10 days away from
either being paralyzed or losing the use of her arms because of
tumours pressing on her spine.

After getting the PET scan results, the couple was in awe as
they walked past examination rooms at the Allan Blair Cancer
Centre.

“Those were the rooms we sat in how many times where we learned
she had cancer,” Graham said. “It was a very strange feeling
walking past those rooms with this freedom. And then we walked
past the packed chemo waiting room, and it felt like we were
prisoners being released from prison and at the same time
knowing that’s a pretty rare thing. The cancer clinic is great
and they’re doing everything they can, but we were conscious
that not too many people walk out of there with the news we
just got.”

The Warners consulted a doctor of natural medicine and, with
the blessing of her oncologist, Dionne started treatments in
Mexico which the couple call comprehensive because they
included chemotherapy.

“The doctor of natural medicine in Regina said, ‘Dionne, you
can walk, talk and move. If I were you, I would either get to
Germany or Mexico for treatment,’ ” she said.

On their first three-week trip to Tijuana, Dionne underwent
major hyperthermia treatment weekly. The process involved
removing her blood gradually and heating it to 43 degrees C.
The blood was passed through ultraviolet light to kill any
bacteria and then re-introduced into her body.

Heat weakens cancer cells, but does not harm healthy cells,
Graham said.

Besides taking vitamins and supplements, Dionne had
chemotherapy treatments and was on a diet that had no gluten,
carbohydrates or dairy products. Consequently, the slender
woman lost a lot of weight, which didn’t please her Regina
oncologist.

“When we explored going back (to Mexico) to try some stem cell
therapy, he was less enthused, but he still assisted me in
pursuing stem cell therapy,” Graham said.

On the couple’s second trip to the Mexican hospital, Dionne had
stem cell therapy. Graham explained a sample of the tumour was
taken, harvested in the lab and a vaccine was made. After a
hyperthermia treatment, Dionne received an injection of the
killer cells, which attacked the cancer.

Graham estimates the first Mexican treatments cost $28,000 US
and the second set were around $22,000 US. In addition, the
couple paid just under $2,700 for each Avastin treatment Dionne
received in Canada. Over two years, she had two to three
Avastin treatments a month.

“I think we’re under this perception that our medical system
pays for everything and will always look after us, but it
didn’t pay for the Avastin, which we think was very effective,”
Graham said. “It would be nice to see the comprehensive
treatment join the traditional.”

Dionne said the treatment worked for her, but emphasized that
every cancer case is unique.

“Dionne’s attitude is the foundation to work from,” Graham
said. “When you have such a positive attitude, you can really
build off of that in pursuing different treatments.”

Since word has spread on social media that Dionne is in
remission, the couple has received hundreds of messages and
emails. Many well wishes have come from people they have never
met, but who have read Never Leave Your Wingman, a book written
by Regina author Deana J. Driver that chronicles the couple’s
story of hope since Dionne was first diagnosed.

“Hope is everything,” Graham said.

“You’ve got to start with your inner self and come out saying,
‘I’m going to do my best to fight back and win this battle and
live life with no regrets,’ ” Dionne added.

"color: inherit; text-decoration: none;" name=
"readabilityLink-1" id=
"readabilityLink-1">pcowan@leaderpost.com
"#readabilityFootnoteLink-1" class="readability-DoNotFootnote"
style="color: inherit;">[1]

© Copyright (c) The Regina Leader-Post

Excerpt from:
Regina woman a walking miracle

BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease

January 28th, 2012 by Starskrinvigit No comments »

JUPITER, Fla., Jan. 23, 2012 /PRNewswire/
 BioRestorative Therapies, Inc. (OTCQB: "/q;_ylt=A0LkuINRESRPIkcASQMIuodG;_ylu=X3oDMTFqMDgxZXM0BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0N2xwbmJyBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMzllZTUxOTMtNzI2Ny0zNzJjLTlkZGItMTMwZmFjYjRiOWYzBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3?s=brtx.pk"
style="color: inherit; text-decoration: none;" name=
"readabilityLink-1" id="readabilityLink-1">BRTX.PK
"#readabilityFootnoteLink-1" class="readability-DoNotFootnote"
style="color: inherit;">[1]
-
"/q/h;_ylt=A0LkuINRESRPIkcASgMIuodG;_ylu=X3oDMTFqaWd2Ymg3BG1pdANBcnRpY2xlIEJvZHkEcG9zAzIEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0N2xwbmJyBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMzllZTUxOTMtNzI2Ny0zNzJjLTlkZGItMTMwZmFjYjRiOWYzBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3?s=brtx.pk"
style="color: inherit; text-decoration: none;" name=
"readabilityLink-2" id="readabilityLink-2">News
"#readabilityFootnoteLink-2" class="readability-DoNotFootnote"
style="color: inherit;">[2]
)
(“BRT”) today announced that it will be presenting at the
Seventh International Conference on Cell Therapy for
Cardiovascular Disease. The event, being held at the New
York-Presbyterian Hospital/Columbia University Medical Center,
is a two-and-a-half-day conference dedicated to the evolving
field of cell-based therapies for the repair and regeneration
of cardiac and vascular disease.

Dr. Amit Patel, Director of Clinical Regenerative Medicine and
Tissue Engineering at the University of Utah and a member of
the BRT Scientific Advisory Board, will be presenting his
findings relating to brown fat stem cells and metabolic
disorders (one of BRT's stem cell initiatives). His talk,
entitled “Metabolic Syndrome: A Role For Cell Therapy,”
will be on Wednesday, January 25th at 1:50 PM.

Mark Weinreb, Chairman and CEO of BRT, has also been selected
to serve on an industry panel and will discuss BRT's
ThermoStem™ Program and the use of brown fat stem cells
as potential therapeutics.  The session will be held on
Thursday, January 26th from 3:15-4:15 PM.

BRT is involved in a research initiative focusing on the use of
Brown Fat stem cells to potentially treat metabolic disorders
and obesity that may lead to heart disease, diabetes,
hypertension, kidney disease and other diseases and disorders.

The Conference will take place January 25-27 at the Vivien and
Seymour Milstein Family Heart Center, Myrna L. Daniels
Auditorium, NYPH/Columbia University Medical Center, 173 Fort
Washington Avenue, First Floor, New York City.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc.'s goal is to become a medical
center of excellence using cell and tissue protocols, primarily
involving a patient's own (autologous) adult stem cells
(non-embryonic), allowing patients to undergo cellular-based
treatments. In June 2011, the Company launched a technology
that involves the use of a brown fat cell-based
therapeutic/aesthetic program, known as the ThermoStem™
Program
.  The ThermoStem™ Program will focus on
treatments for obesity, weight loss, diabetes, hypertension,
other metabolic disorders and cardiac deficiencies and will
involve the study of stem cells, several genes, proteins and/or
mechanisms that are related to these diseases and disorders. As
more and more cellular therapies become standard of care, the
Company believes its strength will be its focus on the unity of
medical and scientific explanations for clinical procedures and
outcomes for future personal medical applications.  The
Company also plans to offer and sell facial creams and products
under the Stem Pearls™ brand.

This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of
1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. You are cautioned
that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the
forward-looking statements as a result of various factors and
other risks, including those set forth in the Company's Form
10, as amended, filed with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in
this release are made as of the date hereof and the Company
undertakes no obligation to update such statements.

CONTACT:
Mark Weinreb
CEO
Tel: (561) 904-6070
Fax: (561) 429-5684

Read the rest here:
BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease

Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy …

January 28th, 2012 by farJBoWQBKlnsqZ No comments »

NEW YORK, Jan. 23, 2012 /PRNewswire/ –  "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QApgQIuodG;_ylu=X3oDMTFqMDgxZXM0BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11b7avurc/EXP=1328973391/**http%3A//www.neostem.com/"
target="_blank" style="color: inherit; text-decoration: none;"
name="readabilityLink-1" id="readabilityLink-1">NeoStem,
Inc.
"readability-DoNotFootnote" style=
"color: inherit;">[1]
(NYSE Amex:
NBS) (“NeoStem” or the “Company”), an international
biopharmaceutical company with a focus on cell-based
therapeutic development, today announced that its Chief Medical
Officer, the lead investigator for its "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QApwQIuodG;_ylu=X3oDMTFqaWd2Ymg3BG1pdANBcnRpY2xlIEJvZHkEcG9zAzIEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=13fu7sj7l/EXP=1328973391/**http%3A//www.neostem.com/clinical-development/amr-001/clinical-trials/preserve-ami-trial.html"
target="_blank" style="color: inherit; text-decoration: none;"
name="readabilityLink-2" id="readabilityLink-2">PreSERVE Phase
2 clinical trial
"readability-DoNotFootnote" style=
"color: inherit;">[2]
for AMR-001
for preservation of heart function in post acute myocardial
infarction patients, and the President of its subsidiary,
"http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QAqAQIuodG;_ylu=X3oDMTFqaTNjbzlmBG1pdANBcnRpY2xlIEJvZHkEcG9zAzMEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11p9b2lvu/EXP=1328973391/**http%3A//www.progenitorcelltherapy.com/"
target="_blank" style="color: inherit; text-decoration: none;"
name="readabilityLink-3" id="readabilityLink-3">Progenitor Cell
Therapy, LLC
"readability-DoNotFootnote" style=
"color: inherit;">[3]
, have been
invited to present at the Seventh International Conference on
Cell Therapy for Cardiovascular Disease held from January
25-27, 2012 in New York City. The event is being organized by
the Cardiovascular Research Foundation and will be held at the
Myrna L. Daniels Auditorium in the Vivien and Seymour Milstein
Family Heart Center at NYPH/Columbia University Medical Center.

According to the conference, the program will be dedicated to
the evolving field of cell-based therapies being developed for
the repair and regeneration of cardiac and vascular disease, as
well as related diseases such as diabetes and stroke. This
year's conference will focus on preclinical and clinical
studies on the path to commercialization, highlighting the
status of molecular, cell, and tissue products in addition to
delivery systems. Leaders from the international community will
convene to present their work, experiences, observations, and
opinions on the benefits and unmet challenges of cell-based
therapies.

Dr. Pecora said, “As a presenter at the first industry
session, I look forward to informing industry leaders about the
PreSERVE Phase 2 clinical trial for AMI which is now open for
enrollment and may provide data readout 18 months from the
first patient enrollment, as well as discussing the recent
patent issued to use the Amorcyte technology beyond
cardiovascular disease.” 

Dr. Robin L. Smith, Chairman and CEO of NeoStem, said, “This
conference represents validation that the development of
cell therapies for diseases outside of bone marrow
transplantation is progressing as represented by their current
clinical data. Our acquisition of Amorcyte last year has
positioned NeoStem to be a leader in the cell therapy
cardiovascular space. We are excited to be a part of the
developing science represented by this important conference and
share our expertise represented by the progress with Amorcyte
and our capabilities to assist the field with the manufacturing
services of PCT.”

About the Cardiovascular Research Foundation

According to the Cardiovascular Research Foundation, their role
in interventional cardiovascular medicine is unique: conducting
research on therapies, pharmacology, and devices during the
earliest stages of development, confirming safety and efficacy
in human clinical trials, and educating the medical community
regarding appropriate use of these new procedures and
technologies. By providing research, evaluation, and education
under one roof, CRF has a unique ability to generate important
research questions, test and refine groundbreaking new
therapies, and ensure that these treatments are available to
patients at the earliest opportunity. For more information,
please visit "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QAqwQIuodG;_ylu=X3oDMTFqY2dxYjVxBG1pdANBcnRpY2xlIEJvZHkEcG9zAzYEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11jfcnm6v/EXP=1328973391/**http%3A//www.celltherapy.crf.org/"
target="_blank" style="color: inherit; text-decoration: none;"
name="readabilityLink-6" id=
"readabilityLink-6">www.celltherapy.crf.org
"#readabilityFootnoteLink-6" class="readability-DoNotFootnote"
style="color: inherit;">[6]
.

About NeoStem, Inc. and Amorcyte, LLC, a NeoStem company

NeoStem, Inc. (“NeoStem”) is a leader in the development and
manufacture of cell therapies. NeoStem has a strategic
combination of revenues, including that which is derived from
the contract manufacturing services performed by Progenitor
Cell Therapy, LLC, a NeoStem company. That manufacturing base
is one of the few cGMP facilities available for contracting in
the burgeoning cell therapy industry, and it is the combination
of PCT's core expertise in manufacturing and NeoStem's
extensive research capabilities that positions the company as a
leader in cell therapy development. Amorcyte, LLC, also a
NeoStem company, is developing a cell therapy for the treatment
of cardiovascular disease. Amorcyte's lead compound, AMR-001,
represents NeoStem's most clinically advanced therapeutic and
is open for enrollment in a Phase 2 trial for the preservation
of heart function after a heart attack.  Amorcyte expects
to begin a Phase 1 clinical trial in 2012 for AMR-001 for the
treatment of patients with congestive heart failure. Athelos
Corporation, also a NeoStem company, is developing a T-cell
therapy for a range of autoimmune conditions with our partner
Becton-Dickinson.  NeoStem's pre-clinical assets include
its VSEL™ Technology platform for regenerative medicine, which
NeoStem believes to be an endogenous, pluripotent,
non-embryonic stem cell that has the potential to change the
paradigm of cell therapy as we know it today.

For more information on NeoStem and Amorcyte, please visit
"http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QArAQIuodG;_ylu=X3oDMTFqZG1vZW1rBG1pdANBcnRpY2xlIEJvZHkEcG9zAzcEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11b7avurc/EXP=1328973391/**http%3A//www.neostem.com/"
target="_blank" style="color: inherit; text-decoration: none;"
name="readabilityLink-7" id=
"readabilityLink-7">www.neostem.com
"#readabilityFootnoteLink-7" class="readability-DoNotFootnote"
style="color: inherit;">[7]
and
"http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QArQQIuodG;_ylu=X3oDMTFqZTJrMXNoBG1pdANBcnRpY2xlIEJvZHkEcG9zAzgEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11c5p0l8l/EXP=1328973391/**http%3A//www.amorcyte.com/"
target="_blank" style="color: inherit; text-decoration: none;"
name="readabilityLink-8" id=
"readabilityLink-8">www.amorcyte.com
"#readabilityFootnoteLink-8" class="readability-DoNotFootnote"
style="color: inherit;">[8]
.

Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management's current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. Forward looking statements
include statements herein with respect to the successful
execution of the Company's business and medical strategy,
including with respect to the successful development of AMR-001
and other cell therapies, about which no assurance can be
given. The Company's actual results could differ materially
from those anticipated in these forward- looking statements as
a result of various factors. Factors that could cause future
results to materially differ from the recent results or those
projected in forward-looking statements include the “Risk
Factors” described in the Company's definitive proxy statement
filed with the Securities and Exchange Commission on September
16, 2011 and in the Company's periodic filings with the
Securities and Exchange Commission. The Company's further
development is highly dependent on future medical and research
developments and market acceptance, which is outside its
control.

readability="4.15217391304">

For more information, please
contact:

 

 

 

Trout Group

NeoStem, Inc.

Gitanjali Jain Ogawa, Vice
President

Robin Smith, CEO

Phone: +1-646-378-2949

Phone: +1-212-584-4174

Email: "mailto:gogawa@troutgroup.com;_ylt=A2KJhz1PESRPx2QArgQIuodG;_ylu=X3oDMTFqcjE2NDhqBG1pdANBcnRpY2xlIEJvZHkEcG9zAzkEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
class="p_a" target="_blank" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-9" id=
"readabilityLink-9">gogawa@troutgroup.com
"#readabilityFootnoteLink-9" class=
"readability-DoNotFootnote" style=
"color: inherit;">[9]

 

Email: "mailto:rsmith@neostem.com;_ylt=A2KJhz1PESRPx2QArwQIuodG;_ylu=X3oDMTFrb2pndWQ3BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEwBHNlYwNNZWRpYUFydGljbGVCb2R5QXNzZW1ibHk-;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
class="p_a" target="_blank" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-10" id=
"readabilityLink-10">rsmith@neostem.com
"#readabilityFootnoteLink-10" class=
"readability-DoNotFootnote" style=
"color: inherit;">[10]

 

References

  1. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QApgQIuodG;_ylu=X3oDMTFqMDgxZXM0BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11b7avurc/EXP=1328973391/**http%3A//www.neostem.com/"
    target="_blank" name="readabilityFootnoteLink-1" id=
    "readabilityFootnoteLink-1">NeoStem, Inc.

    (us.lrd.yahoo.com)
  2. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QApwQIuodG;_ylu=X3oDMTFqaWd2Ymg3BG1pdANBcnRpY2xlIEJvZHkEcG9zAzIEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=13fu7sj7l/EXP=1328973391/**http%3A//www.neostem.com/clinical-development/amr-001/clinical-trials/preserve-ami-trial.html"
    target="_blank" name="readabilityFootnoteLink-2" id=
    "readabilityFootnoteLink-2">PreSERVE Phase 2 clinical
    trial
    (us.lrd.yahoo.com)
  3. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QAqAQIuodG;_ylu=X3oDMTFqaTNjbzlmBG1pdANBcnRpY2xlIEJvZHkEcG9zAzMEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11p9b2lvu/EXP=1328973391/**http%3A//www.progenitorcelltherapy.com/"
    target="_blank" name="readabilityFootnoteLink-3" id=
    "readabilityFootnoteLink-3">Progenitor Cell Therapy, LLC

    (us.lrd.yahoo.com)
  4. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QAqQQIuodG;_ylu=X3oDMTFqc2Fobm1zBG1pdANBcnRpY2xlIEJvZHkEcG9zAzQEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=13fu7sj7l/EXP=1328973391/**http%3A//www.neostem.com/clinical-development/amr-001/clinical-trials/preserve-ami-trial.html"
    target="_blank" name="readabilityFootnoteLink-4" id=
    "readabilityFootnoteLink-4">PreSERVE AMI Phase 2 trial

    (us.lrd.yahoo.com)
  5. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QAqgQIuodG;_ylu=X3oDMTFqaGFmbHBnBG1pdANBcnRpY2xlIEJvZHkEcG9zAzUEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11p9b2lvu/EXP=1328973391/**http%3A//www.progenitorcelltherapy.com/"
    target="_blank" name="readabilityFootnoteLink-5" id=
    "readabilityFootnoteLink-5">Progenitor Cell Therapy

    (us.lrd.yahoo.com)
  6. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QAqwQIuodG;_ylu=X3oDMTFqY2dxYjVxBG1pdANBcnRpY2xlIEJvZHkEcG9zAzYEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11jfcnm6v/EXP=1328973391/**http%3A//www.celltherapy.crf.org/"
    target="_blank" name="readabilityFootnoteLink-6" id=
    "readabilityFootnoteLink-6">www.celltherapy.crf.org

    (us.lrd.yahoo.com)
  7. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QArAQIuodG;_ylu=X3oDMTFqZG1vZW1rBG1pdANBcnRpY2xlIEJvZHkEcG9zAzcEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11b7avurc/EXP=1328973391/**http%3A//www.neostem.com/"
    target="_blank" name="readabilityFootnoteLink-7" id=
    "readabilityFootnoteLink-7">www.neostem.com

    (us.lrd.yahoo.com)
  8. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KJhz1PESRPx2QArQQIuodG;_ylu=X3oDMTFqZTJrMXNoBG1pdANBcnRpY2xlIEJvZHkEcG9zAzgEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11c5p0l8l/EXP=1328973391/**http%3A//www.amorcyte.com/"
    target="_blank" name="readabilityFootnoteLink-8" id=
    "readabilityFootnoteLink-8">www.amorcyte.com

    (us.lrd.yahoo.com)
  9. "Jump to Link in Article">^ "mailto:gogawa@troutgroup.com;_ylt=A2KJhz1PESRPx2QArgQIuodG;_ylu=X3oDMTFqcjE2NDhqBG1pdANBcnRpY2xlIEJvZHkEcG9zAzkEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
    class="p_a" target="_blank" name="readabilityFootnoteLink-9"
    id="readabilityFootnoteLink-9">gogawa@troutgroup.com

    (finance.yahoo.com)
  10. "Jump to Link in Article">^ "mailto:rsmith@neostem.com;_ylt=A2KJhz1PESRPx2QArwQIuodG;_ylu=X3oDMTFrb2pndWQ3BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEwBHNlYwNNZWRpYUFydGljbGVCb2R5QXNzZW1ibHk-;_ylg=X3oDMTJ0MnJwY2lnBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDMDhiYmQxM2YtOWI3ZS0zNjQ0LTg4MDEtM2M3MjczZmRlNThiBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
    class="p_a" target="_blank" name="readabilityFootnoteLink-10"
    id="readabilityFootnoteLink-10">rsmith@neostem.com

    (finance.yahoo.com)

Read this article:
Senior Management of NeoStem and Its Subsidiaries Invited to Speak at Seventh International Conference on Cell Therapy …

Cell Society International Hosts its 2nd Annual Clinical Conference in San Diego, CA, to Discuss Clinical Advancements …

January 28th, 2012 by dMNdFulQzbzseicv No comments »

LA JOLLA, Calif., Jan. 25, 2012 /PRNewswire/ – Interest
in adult stem
cell
therapies and their clinical applicability in
treating and helping patients is growing, while accurate
information remains difficult to access.  "http://us.lrd.yahoo.com/_ylt=A2KLJPT46SNPPD4AfgQIuodG;_ylu=X3oDMTFqMDgxZXM0BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0ZzByaWFvBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDNjE1MDEwZmYtYjE5NC0zOTgwLTg0NTEtZWY0Yjg2NDkwOWYxBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11fp5u23v/EXP=1328963320/**http%3A//www.cellsociety.org/"
target="_blank" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-1" id="readabilityLink-1">Cell Society
International
"readability-DoNotFootnote" style=
"color: inherit;">[1]
, a
nonprofit organization, is dedicated to advancing the
clinical applications of adult stem cell therapies worldwide
through education and the collaboration of world thought
leaders.

According to Emerson C. Perin, MD, PhD, Director,
Clinical
Research for Cardiovascular Medicine
and Medical
Director, Stem
Cell Institute, Texas Heart Institute
, Houston, TX and
member of the Board of Directors of Cell Society, ”We
obtained remarkable results from our study in which we
injected stem cells derived from the bone marrow of a healthy
donor into patients with heart failure. Heart function and
exercise capacity improved in some cell-treated patients.
Most importantly, cell therapy significantly reduced cardiac
adverse events, including death. Three of 15 (20%) control
patients died of cardiac causes, whereas only 1 of 45 (2%)
cell-treated patients had a cardiac-related death. Despite
the small numbers, our findings showed that cell therapy
significantly improved cardiac mortality.” 

The 2nd Annual Clinical Meeting of id="lw_1327491260_3">Cell Society will be held at the
Coronado Island Marriott Resort in San Diego, California on
February 17 – 18, 2012.  International and national
clinical researchers and thought leaders will share current
information on adult stem cell applications in a variety of
therapeutic categories The two-day conference will offer
clinical updates on cell therapies in plastic surgery, wound
healing, cardiac disease, stroke, MS, bone healing and
cartilage regeneration, to name a few, as well as industry
updates from leading developers of cell therapies and medical
devices.  The second day includes a panel discussion
titled The Practice of Medicine and Government
Regulation: The Rubicon
as well as a session focused on
the Future of "lw_1327491260_2">Stem Cell Therapy in the United
States
. Leading experts from around the globe will
discuss the challenges facing all who are involved in the
advancement of regenerative medicine through the use of stem
cell therapy.  Up to 11.5 CME credits will be available
for attendees.

About Cell Society International:  Cell Society was
formed in May 2010, to serve as an independent source of
educational information for all interested in clinically
relevant adult stem cell therapy applications.  As a
nonprofit mutual benefit corporation, Cell Society will
utilize the expertise of its industry relationships as well
as the cooperation of patients, their physicians and world
thought leaders to advance the clinical applications of adult
stem cell therapies worldwide.  For more information
about registration and sponsorship for the 2nd Annual
Clinical Meeting please visit "http://us.lrd.yahoo.com/_ylt=A2KLJPT46SNPPD4AfwQIuodG;_ylu=X3oDMTFqaWd2Ymg3BG1pdANBcnRpY2xlIEJvZHkEcG9zAzIEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0ZzByaWFvBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDNjE1MDEwZmYtYjE5NC0zOTgwLTg0NTEtZWY0Yjg2NDkwOWYxBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11mt6sj6p/EXP=1328963320/**http%3A//xmedicacme.com/cell_society"
target="_blank" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-2" id=
"readabilityLink-2">http://xmedicacme.com/cell_society
or
contact "mailto:info@xMedicaCME.com;_ylt=A2KLJPT46SNPPD4AgAQIuodG;_ylu=X3oDMTFqaTNjbzlmBG1pdANBcnRpY2xlIEJvZHkEcG9zAzMEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0ZzByaWFvBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDNjE1MDEwZmYtYjE5NC0zOTgwLTg0NTEtZWY0Yjg2NDkwOWYxBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
target="_blank" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-3" id=
"readabilityLink-3">info@xMedicaCME.com
"#readabilityFootnoteLink-2" class=
"readability-DoNotFootnote" style=
"color: inherit;">[2]
"#readabilityFootnoteLink-3" class=
"readability-DoNotFootnote" style=
"color: inherit;">[3]

References

  1. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KLJPT46SNPPD4AfgQIuodG;_ylu=X3oDMTFqMDgxZXM0BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0ZzByaWFvBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDNjE1MDEwZmYtYjE5NC0zOTgwLTg0NTEtZWY0Yjg2NDkwOWYxBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11fp5u23v/EXP=1328963320/**http%3A//www.cellsociety.org/"
    target="_blank" name="readabilityFootnoteLink-1" id=
    "readabilityFootnoteLink-1">Cell Society International

    (us.lrd.yahoo.com)
  2. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KLJPT46SNPPD4AfwQIuodG;_ylu=X3oDMTFqaWd2Ymg3BG1pdANBcnRpY2xlIEJvZHkEcG9zAzIEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0ZzByaWFvBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDNjE1MDEwZmYtYjE5NC0zOTgwLTg0NTEtZWY0Yjg2NDkwOWYxBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=11mt6sj6p/EXP=1328963320/**http%3A//xmedicacme.com/cell_society"
    target="_blank" name="readabilityFootnoteLink-2" id=
    "readabilityFootnoteLink-2">http://xmedicacme.com/cell_society

    (us.lrd.yahoo.com)
  3. "Jump to Link in Article">^ "mailto:info@xMedicaCME.com;_ylt=A2KLJPT46SNPPD4AgAQIuodG;_ylu=X3oDMTFqaTNjbzlmBG1pdANBcnRpY2xlIEJvZHkEcG9zAzMEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0ZzByaWFvBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDNjE1MDEwZmYtYjE5NC0zOTgwLTg0NTEtZWY0Yjg2NDkwOWYxBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
    target="_blank" name="readabilityFootnoteLink-3" id=
    "readabilityFootnoteLink-3">info@xMedicaCME.com

    (finance.yahoo.com)

Continue reading here:
Cell Society International Hosts its 2nd Annual Clinical Conference in San Diego, CA, to Discuss Clinical Advancements …

Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing

January 28th, 2012 by Lycleeagery No comments »

ALLENDALE, N.J., "xn-chron">Jan. 12, 2012 /PRNewswire/ — NeoStem's cell
therapy manufacturing division, Progenitor Cell Therapy
(“PCT”), a NeoStem, Inc. company (NYSE Amex: NBS) (“NeoStem” or
the “Company”), announced today an agreement whereby PCT will
provide contract manufacturing and regulatory services related
to the development of Islet Sciences – PTM, which will be an
injectable suspension of microencapsulated insulin-producing,
pancreatic islet cells which are harvested from designated
pathogen free pigs. As part of this arrangement, PCT will
perform microencapsulation for parsing beta pancreatic islets
for xenotransplantation using piglet pancreata. Islet Sciences,
Inc. (“Islet”) is a biotechnology company engaged in the
research, development and commercialization of patented
technologies in the field of transplantation therapy for
patients with diabetes and is a wholly-owned subsidiary of One
E-Commerce Corporation (OTCBB: "/q;_ylt=A2KLJOXr6SNP3S4APgMIuodG;_ylu=X3oDMTFqMDgxZXM0BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3?s=once.ob"
style="color: inherit; text-decoration: none;" name=
"readabilityLink-1" id="readabilityLink-1">ONCE.OB
"#readabilityFootnoteLink-1" class="readability-DoNotFootnote"
style="color: inherit;">[1]
-
"/q/h;_ylt=A2KLJOXr6SNP3S4APwMIuodG;_ylu=X3oDMTFqaWd2Ymg3BG1pdANBcnRpY2xlIEJvZHkEcG9zAzIEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3?s=once.ob"
style="color: inherit; text-decoration: none;" name=
"readabilityLink-2" id="readabilityLink-2">News
"#readabilityFootnoteLink-2" class="readability-DoNotFootnote"
style=
"color: inherit;">[2]
). 

A 2010 study by the CDC found that approximately 25.8 million
Americans, more than 8% of the population, were affected by
diabetes. 5% of this number, approximately 1.3 million, have
type 1 diabetes. Type 1 diabetes is estimated to cost the US
$14.4 billion total annually.

“Given the robust market opportunity and the potential for cell
therapy to alter the disease paradigm, NeoStem has agreed to
this novel arrangement whereby PCT will subsidize manufacturing
margin related to current services for Islet Sciences – PTM
product in exchange for royalties on future sales, exclusive
manufacturing rights for both clinical trial and commercial
manufacturing and an equity stake in Islet's parent. We
recognize that PCT's track record of developing cell therapies
cost efficiently for cell therapy companies makes this a truly
compelling opportunity in the industry,” said "xn-person">John Steel, CEO of Islet Sciences.

“Our team looks forward to applying its process and assay
expertise, in partnership with the scientific expertise of Dr.
Jonathan Lakey, scientific
advisor to Islet, and his team, towards the development of this
novel and creative cellular therapeutic for the treatment of
type 1 diabetes,” said Robert A.
Preti
, PhD, President of PCT. ”We are honored that
Islet Sciences has enlisted PCT to provide manufacturing and
development support as it advances this important product
through clinical development.”  

Dr. Robin L. Smith, Chairman and
CEO of NeoStem, added, “We are excited to begin using our
manufacturing currency at PCT to support important technologies
with promise by providing manufacturing and regulatory support
at a reduced profit margin in exchange for participation in
future royalties, equity as well as a commitment for clinical
trial and commercial manufacturing exclusivity.”

About Type 1 Diabetes

According to the American Diabetes Association, type 1
diabetes, previously called insulin-dependent diabetes mellitus
(IDDM) or juvenile diabetes, is an autoimmune disease
characterized by insulin deficiency resulting from destruction
of beta-cells in the pancreas, ultimately resulting in the
body's inability to convert consumed sugar and starches into
energy. This form of diabetes usually affects children and
young adults, but it can occur at any age. Although insulin
therapy and other treatments can be used to manage the
condition, the condition is currently incurable.  

About NeoStem, Inc.

NeoStem, Inc. (“NeoStem”) is a leader in the development and
manufacture of cell therapies. NeoStem has a strategic
combination of revenues, including that which is derived from
the contract manufacturing services performed by Progenitor
Cell Therapy, LLC, a NeoStem company. That manufacturing base
is one of the few cGMP facilities available for contracting in
the burgeoning cell therapy industry, and it is the combination
of PCT's core expertise in manufacturing and NeoStem's
extensive research capabilities that positions the company as a
leader in cell therapy development. Amorcyte, Inc., also a
NeoStem company, is developing a cell therapy for the treatment
of cardiovascular disease. Amorcyte's lead compound, AMR-001,
represents NeoStem's most clinically advanced therapeutic
and  has commenced enrollment in a Phase 2 trial for the
preservation of heart function after a heart attack.
 Amorcyte expects to begin a Phase 1 clinical trial in
2012 for AMR-001 for the treatment of patients with congestive
heart failure. Athelos Corporation, also a NeoStem company, is
developing a T-cell therapy for a range of autoimmune
conditions with its partner Becton-Dickinson.  NeoStem's
pre-clinical assets include its VSEL™ Technology platform for
regenerative medicine, which NeoStem believes to be an
endogenous, pluripotent, non-embryonic stem cell that has the
potential to change the paradigm of cell therapy as we know it
today.

For more information on NeoStem, please visit "http://us.lrd.yahoo.com/_ylt=A2KLJOXr6SNP3S4AQAMIuodG;_ylu=X3oDMTFqaTNjbzlmBG1pdANBcnRpY2xlIEJvZHkEcG9zAzMEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=16anudgta/EXP=1328963307/**http%3A//r20.rs6.net/tn.jsp%3Fllr=eqxmyrdab%26et=1109041081723%26s=0%26e=0015nt3NVBQ96YaMQckR1oe2qZaQjsw8L28rkilDq35daHcCq1pqZzrqSkN9B7spbtbYVb2zlDj_fGeMjoqWxACBfDPi64M-5AXFjTaSfPahew="
target="_blank" style="color: inherit; text-decoration: none;"
name="readabilityLink-3" id=
"readabilityLink-3">www.neostem.com
"#readabilityFootnoteLink-3" class="readability-DoNotFootnote"
style="color: inherit;">[3]
.

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company
with patented technologies focused on transplantation therapy
for people with insulin-dependent diabetes. Islet's
transplantation technology includes methods for the culturing,
isolation, maturation, and immunoprotection
(microencapsulation) of islet cells. Islet's mission includes
the introduction of commercial products with applications to
cell-based replacement therapy in the healthcare marketplace.

Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements for NeoStem, PCT and Islet
Sciences reflect their respective managements' current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. Forward looking statements
include statements herein with respect to the companies'
successful execution of their  respective business
strategies, including with respect to the successful
development of cell therapeutics, including with respect to
Islet Sciences – PTM, as well as the future of the cell
therapeutics industry. Actual results could differ materially
from those anticipated in these forward- looking statements as
a result of various factors. Factors that could cause future
results to materially differ from the recent results or those
projected in forward-looking statements for NeoStem and PCT
include the “Risk Factors” described in NeoStem's prospectus
supplement filed with the Securities and Exchange Commission
(“SEC”) on September 30, 2011 and
for Islet include the risks described in the One E-Commerce
Corporation Form 8-K filed with the Securities and Exchange
Commission on December 30, 2011.
The companies' further development is highly dependent on
future medical and research developments and market acceptance,
which is outside their control.

"4.140969163">

For more information, please
contact:

 

 

 

Trout Group

NeoStem, Inc.

Gitanjali Jain Ogawa, Vice
President

Robin Smith, CEO

Phone: +1-646-378-2949

Phone: +1-212-584-4174

Email: "mailto:gogawa@troutgroup.com;_ylt=A2KLJOXr6SNP3S4AQQMIuodG;_ylu=X3oDMTFqc2Fobm1zBG1pdANBcnRpY2xlIEJvZHkEcG9zAzQEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
class="prnews_a" target="_blank" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-4" id=
"readabilityLink-4">gogawa@troutgroup.com
"#readabilityFootnoteLink-4" class=
"readability-DoNotFootnote" style=
"color: inherit;">[4]

Email: "mailto:rsmith@neostem.com;_ylt=A2KLJOXr6SNP3S4AQgMIuodG;_ylu=X3oDMTFqaGFmbHBnBG1pdANBcnRpY2xlIEJvZHkEcG9zAzUEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
class="prnews_a" target="_blank" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-5" id=
"readabilityLink-5">rsmith@neostem.com
"#readabilityFootnoteLink-5" class=
"readability-DoNotFootnote" style=
"color: inherit;">[5]

References

  1. "Jump to Link in Article">^ "/q;_ylt=A2KLJOXr6SNP3S4APgMIuodG;_ylu=X3oDMTFqMDgxZXM0BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3?s=once.ob"
    name="readabilityFootnoteLink-1" id=
    "readabilityFootnoteLink-1">ONCE.OB

    (finance.yahoo.com)
  2. "Jump to Link in Article">^ "/q/h;_ylt=A2KLJOXr6SNP3S4APwMIuodG;_ylu=X3oDMTFqaWd2Ymg3BG1pdANBcnRpY2xlIEJvZHkEcG9zAzIEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3?s=once.ob"
    name="readabilityFootnoteLink-2" id=
    "readabilityFootnoteLink-2">News

    (finance.yahoo.com)
  3. "Jump to Link in Article">^ "http://us.lrd.yahoo.com/_ylt=A2KLJOXr6SNP3S4AQAMIuodG;_ylu=X3oDMTFqaTNjbzlmBG1pdANBcnRpY2xlIEJvZHkEcG9zAzMEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=16anudgta/EXP=1328963307/**http%3A//r20.rs6.net/tn.jsp%3Fllr=eqxmyrdab%26et=1109041081723%26s=0%26e=0015nt3NVBQ96YaMQckR1oe2qZaQjsw8L28rkilDq35daHcCq1pqZzrqSkN9B7spbtbYVb2zlDj_fGeMjoqWxACBfDPi64M-5AXFjTaSfPahew="
    target="_blank" name="readabilityFootnoteLink-3" id=
    "readabilityFootnoteLink-3">www.neostem.com

    (us.lrd.yahoo.com)
  4. "Jump to Link in Article">^ "mailto:gogawa@troutgroup.com;_ylt=A2KLJOXr6SNP3S4AQQMIuodG;_ylu=X3oDMTFqc2Fobm1zBG1pdANBcnRpY2xlIEJvZHkEcG9zAzQEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
    class="prnews_a" target="_blank" name=
    "readabilityFootnoteLink-4" id=
    "readabilityFootnoteLink-4">gogawa@troutgroup.com

    (finance.yahoo.com)
  5. "Jump to Link in Article">^ "mailto:rsmith@neostem.com;_ylt=A2KLJOXr6SNP3S4AQgMIuodG;_ylu=X3oDMTFqaGFmbHBnBG1pdANBcnRpY2xlIEJvZHkEcG9zAzUEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0aDE0ZTNoBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjM0ODZlODktNzdhZC0zZjQyLTk0NjMtMzNlODU3N2YxMDFjBHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=3"
    class="prnews_a" target="_blank" name=
    "readabilityFootnoteLink-5" id=
    "readabilityFootnoteLink-5">rsmith@neostem.com

    (finance.yahoo.com)

Here is the original post:
Islet Sciences, Inc. Selects NeoStem's Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing

Eye Study Is a Small but Crucial Advance for Stem-Cell Therapy

January 28th, 2012 by healthcoach No comments »
alt="" class="photo">

Safety first: Robert Lanza, chief scientific officer
of Advanced Cell Technology, says the two patients in an
early stage of a stem-cell study have shown no negative side
effects from the treatment.
Advanced Cell Technology

Eye Study Is a Small but Crucial Advance for Stem-Cell Therapy

The results show that the treatment can be safe, but whether it
can be effective is another question.

  • Wednesday, January 25, 2012
  • By Karen Weintraub

The first published clinical trial of stem-cell therapy is a
tremendous boon to the company leading the experiment—but it's
only a small step forward for the field.

In a paper published this week in The Lancet,
scientists from the David Geffen School of Medicine at the
University of California, Los Angeles, and from "http://www.advancedcell.com/" target="_blank" style=
"color: inherit; text-decoration: none;" name=
"readabilityLink-1" id="readabilityLink-1">Advanced Cell
Technology
"readability-DoNotFootnote" style=
"color: inherit;">[1]
, in
Marlborough, Massachusetts, reported that two patients each
safely received injections of embryonic stem cells into an eye.

Stem-cell research in patients suffered a major blow recently,
when one leading company, target="_blank" style="color: inherit; text-decoration: none;"
name="readabilityLink-2" id=
"readabilityLink-2">Geron
"#readabilityFootnoteLink-2" class="readability-DoNotFootnote"
style="color: inherit;">[2]
,
style="color: inherit; text-decoration: none;" name=
"readabilityLink-3" id="readabilityLink-3">pulled out of a
pioneering spinal cord repair study
"#readabilityFootnoteLink-3" class="readability-DoNotFootnote"
style=
"color: inherit;">[3]
. The
new study is more limited in scope, focusing on treatment that
is easier to study and less problematic.  

The new study was written three months after treating the
patients, both of whom have degenerative eye diseases and
limited sight. Another three months has now passed, and
"_blank" style="color: inherit; text-decoration: none;" name=
"readabilityLink-4" id="readabilityLink-4">Robert
Lanza
"readability-DoNotFootnote" style=
"color: inherit;">[4]
, chief
scientific officer of Advanced Cell Technology, says both are
still doing well, with no apparent side effects.

Lanza says Advanced Cell Technology would not commercialize the
work itself, but would look to partner with a company that
would.

The intent of the study was to show that the treatment is safe,
not to look at its effectiveness. But Lanza, the paper, and a
related commentary also published in The Lancet all
cited the women's reports of benefits from the procedure. One
woman's vision improved enough to see a hand waved in front of
her face; the other climbed from 20/500 to 20/320 on an eye
chart.

style="color: inherit; text-decoration: none;" name=
"readabilityLink-5" id="readabilityLink-5">Kevin
Eggan
"readability-DoNotFootnote" style=
"color: inherit;">[5]
, an
associate professor of stem cell and regenerative biology at
Harvard University, says he's surprised that The
Lancet
published such preliminary results, and that
scientists are talking about the treatment's effectiveness at
such an early stage of research.

Read the original here:
Eye Study Is a Small but Crucial Advance for Stem-Cell Therapy

Stem Cell Eye Therapy Shows Promise

January 28th, 2012 by Urgedekag No comments »

Reporting inThe Lancet, researchers write that a
preliminary study shows embryonic stem cell therapy in two
patients with macular degeneration was safe. Results suggest
the patients' vision improved slightly. Dr. Robert Lanza, Chief
Scientific Officer of Advanced Cell Technology and co-author of
the study, discusses the trial.

Here is the original post:
Stem Cell Eye Therapy Shows Promise

Vet-Stem Announces Milestone of 8,000 Animals Treated With Vet-Stem Cell Therapy

January 28th, 2012 by Lerrietramutt No comments »

POWAY, CA–(Marketwire -01/27/12)- Vet-Stem, Inc. today
announced that over 8,000 animals have now been treated with
Vet-Stem cell therapy.

Vet-Stem began providing stem cells to veterinarians in 2004
and has now provided stem cells for the treatment of over
8,000 animals. Vet-Stem was the first company to introduce
rapid turnaround stem cell services in the US. After
providing stem cells for thousands of horses, Vet-Stem
pioneered stem cell therapy in dogs and cats and is now the
world leader in Regenerative Veterinary Medicine™. The rapid
adoption of stem cell therapy by equine veterinarians and
horse owners provided a springboard for use in small animal
veterinary medicine.

Greater than 75% of horses treated with Vet-Stem cell therapy
for tendon and ligament injuries are able to return to their
previous level of performance. Dog owners report that greater
than 80% of dogs treated with Vet-Stem cell therapy have an
improved quality of life.

“We are proud that so many dog, horse, and cat owners as well
as veterinarians have placed their trust in Vet-Stem cell
therapy. We feel a great sense of accomplishment knowing that
there are now over 8,000 horse and pet owners who have
experienced the benefit of stem cell technology. This
practical and beneficial application of technology puts stem
cell therapy into the present day instead of a future
theoretical concept,” said Bob Harman, DVM, MPVM, Founder and
CEO of Vet-Stem.

Vet-Stem is now working with small animal veterinarians to
develop other life-saving uses for stem cell therapy for
injuries and diseases that currently have few treatment
options.

More information about Vet-Stem can be found at "http://us.lrd.yahoo.com/_ylt=A2KLJZjn6SNP7QkAoAGVuodG;_ylu=X3oDMTFqMDgxZXM0BG1pdANBcnRpY2xlIEJvZHkEcG9zAzEEc2VjA01lZGlhQXJ0aWNsZUJvZHlBc3NlbWJseQ--;_ylg=X3oDMTJ0MTZla2NzBGludGwDdXMEbGFuZwNlbi11cwRwc3RhaWQDZjIwMmFjOWEtYTQzMi0zNTZmLWFiNmQtYzYwZTMyYThkNjg0BHBzdGNhdANuZXdzBHB0A3N0b3J5cGFnZQR0ZXN0Aw--;_ylv=0/SIG=144d9odqt/EXP=1328963303/**http%3A//ctt.marketwire.com/%3Frelease=845502%26id=1203007%26type=1%26url=http%253a%252f%252fwww.vet-stem.com%252f"
style="color: inherit; text-decoration: none;" name=
"readabilityLink-1" id=
"readabilityLink-1">www.Vet-Stem.com
"#readabilityFootnoteLink-1" class=
"readability-DoNotFootnote" style=
"color: inherit;">[1]

About Vet-Stem, Inc.:
Vet-Stem, Inc. was formed in
2002 to bring regenerative medicine to the veterinary
profession. This privately held company delivers stem cell
and related services and products to veterinarians to treat
diseases in dogs, cats and horses. These technologies utilize
the natural healing properties inherent in all animals to
reduce pain and improve the quality of life of our animal
companions. Published studies have confirmed that
adipose-derived stem cells can dramatically improve the
healing of injuries and diseases that have had very few
treatment options in the past.

Vet-Stem holds the exclusive worldwide veterinary rights to
the Artecel (University of Pittsburgh) and University of
California adipose stem cell patent portfolio of over 55
issued patents.

See the article here:
Vet-Stem Announces Milestone of 8,000 Animals Treated With Vet-Stem Cell Therapy

Judy’s MS Story – Video

January 27th, 2012 by toorbisteee No comments »


23-01-2012 19:34 Judy shares her story about her son Bruce who passed away in 2010 after a battle with an incredibly aggressive form of multiple sclerosis (MS). Bruce was only in his early 30′s. Judy is a loving mother who is very thankful to MS Queensland who cared for Bruce up until his death at their long term care facility, Granston Lodge in Dutton Park on Brisbane’s southside.

See the rest here:
Judy’s MS Story – Video

Rebif® For Early Symptoms Of Multiple Sclerosis, UK

January 27th, 2012 by PZuQdKhxswWJyet No comments »

Rebif® (interferon beta-1a), a disease-modifying medication used to treat relapsing forms of multiple Sclerosis (MS), is now available in the UK to treat individuals with clinically isolated syndrome (CIS), a potential early indicator of MS, announced Merck Serono, a division of Merck KGaA, Darmstadt, Germany. The announcement comes after the recent positive opinion adopted by the Committee of …

Go here to read the rest:
Rebif® For Early Symptoms Of Multiple Sclerosis, UK

Muscling in on multiple sclerosis

January 27th, 2012 by Zarin4588 No comments »

Multiple sclerosis (MS), a neurodegenerative disease, causes periodic attacks of neurologic symptoms such as limb weakness and mobility defects.

See original here:
Muscling in on multiple sclerosis

Craig Venter: Understanding Our Genes – A Step to Personalized Medicine | CIRM Spotlight on Genomics – Video

January 27th, 2012 by endeatpertews No comments »


24-01-2012 10:25 On January 17th, 2012, the CIRM Governing Board heard from scientists and a patient about the essential role of genomics in the development of stem cell based therapies.

Read more:
Craig Venter: Understanding Our Genes – A Step to Personalized Medicine | CIRM Spotlight on Genomics – Video

World-Renowned Cell-Therapy Researcher, Doris Taylor, PhD, Joins Texas Heart Institute at St. Luke’s Episcopal Hospital

January 27th, 2012 by free credit report No comments »

HOUSTON–(BUSINESS WIRE)– Officials at the Texas Heart Institute (THI) at St.

View original post here:
World-Renowned Cell-Therapy Researcher, Doris Taylor, PhD, Joins Texas Heart Institute at St. Luke’s Episcopal Hospital

MS Biology Project – Video

January 26th, 2012 by AttigFloomo No comments »


19-01-2012 19:53 A project i did for my Biology class LoL it’s about Multiple Sclerosis and the song used is Strobe (club edit) by Deadmau5 i dont own the song.

Read more:
MS Biology Project – Video

Join Team WTOC for MS Walk Savannah to fight multiple sclerosis

January 26th, 2012 by EsseloCog No comments »

The MS Walk Savannah is at the end of March, but fund-raising has begun.

Read more:
Join Team WTOC for MS Walk Savannah to fight multiple sclerosis

ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple …

January 26th, 2012 by zgAoYxiVmRgIlvdH No comments »

Biogen Idec and Elan Corporation, plc today announced a global Phase 3b study, ASCEND, that is being conducted to evaluate the effectiveness of TYSABRI as a treatment for secondary-progressive multiple sclerosis .

See the original post here:
ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progressive Multiple …

Ontario's first cardiac stem cell transplant performed last week at the Peter Munk Cardiac Centre

January 26th, 2012 by guilikive No comments »

Peter Munk Cardiac Centre physicians performed the first cardiac stem cell transplant in Ontario, part of the IMPACT-CABG clinical trial, to treat advanced heart failure, using stem cells derived from the patient's bone marrow, isolated within the operating room, and implanted into the heart at the time of coronary bypass surgery. Researchers hope that stem cell therapy may be developed into a …

Read more from the original source:
Ontario's first cardiac stem cell transplant performed last week at the Peter Munk Cardiac Centre

Current Use of FDA-Approved Pharmacotherapy for MS-Related Symptoms Is Low, Regardless of the High Need Reported by US …

January 25th, 2012 by Fenueupsels No comments »

The prevalence of most multiple sclerosis -related symptoms tends to increase with disease progression, with walking impairment, fatigue, muscle weakness, and spasticity being the most common symptoms among progressive MS patients.

See the rest here:
Current Use of FDA-Approved Pharmacotherapy for MS-Related Symptoms Is Low, Regardless of the High Need Reported by US …

ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at …

January 25th, 2012 by jktkafvky No comments »

Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, announced today the dosing of an additional patient in its Phase 1/2 trial for Stargardt’s macular dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells .

Continue reading here:
ACT Announces that Additional Patient with Stargardt’s Disease Has Undergone Embryonic Stem Cell Transplantation at …






Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research